Earnings results for PMV Pharmaceuticals (NASDAQ:PMVP)
PMV Pharmaceuticals, Inc. is estimated to report earnings on 08/13/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.29.
PMV Pharmaceuticals last released its quarterly earnings data on May 14th, 2021. The reported ($0.26) earnings per share for the quarter, hitting the consensus estimate of ($0.26). PMV Pharmaceuticals has generated ($2.40) earnings per share over the last year. Earnings for PMV Pharmaceuticals are expected to decrease in the coming year, from ($1.22) to ($1.55) per share. PMV Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, August 13th, 2021 based off prior year’s report dates.
Analyst Opinion on PMV Pharmaceuticals (NASDAQ:PMVP)
6 Wall Street analysts have issued ratings and price targets for PMV Pharmaceuticals in the last 12 months. Their average twelve-month price target is $48.75, predicting that the stock has a possible upside of 41.51%. The high price target for PMVP is $63.00 and the low price target for PMVP is $34.00. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus rating of “Buy.”
PMV Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings. According to analysts’ consensus price target of $48.75, PMV Pharmaceuticals has a forecasted upside of 41.5% from its current price of $34.45. PMV Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.
Dividend Strength: PMV Pharmaceuticals (NASDAQ:PMVP)
PMV Pharmaceuticals does not currently pay a dividend. PMV Pharmaceuticals does not have a long track record of dividend growth.
Insiders buying/selling: PMV Pharmaceuticals (NASDAQ:PMVP)
In the past three months, PMV Pharmaceuticals insiders have sold more of their company’s stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $11,850,468.00 in company stock. 21.80% of the stock of PMV Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. 88.63% of the stock of PMV Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of PMV Pharmaceuticals (NASDAQ:PMVP
Earnings for PMV Pharmaceuticals are expected to decrease in the coming year, from ($1.22) to ($1.55) per share. The P/E ratio of PMV Pharmaceuticals is -14.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of PMV Pharmaceuticals is -14.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. PMV Pharmaceuticals has a P/B Ratio of 4.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.
More latest stories: here